| Vol. 12.12 – 6 April, 2021 |
| |
|
|
| The authors revealed that LC3-II formation and SQSTM1/p62 degradation were noted in H2O2-activated human platelets, which could be blocked by 3-methyladenine and bafilomycin A1, indicating that platelet activation may cause platelet autophagy. [Autophagy] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Using single-cell RNA-sequencing, researchers deciphered a dynamic atlas covering 28,777 cells and nine major cell types of zebrafish caudal hematopoietic tissue. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Scientists found that leukemic stem cells in chronic myelomonocytic leukemia resided in a CD34+/CD38− fraction of the malignant clone. [Leukemia] |
|
|
|
| Investigators found increased nitric oxide during HSC regeneration with an accumulation of protein aggregation. [Cell Reports] |
|
|
|
| Researchers performed an shRNA screen in vitro and in vivo in T-cell acute lymphoblastic leukemia cell lines and patient derived xenograft samples to identify vulnerabilities in the pTCR/TCR pathway and identified a critical role for the kinase LCK in cell proliferation. [Haematologica] |
|
|
|
| By using the Eµ-TCL1 adoptive transfer mouse model of chronic lymphocytic leukemia, scientists observed that ibrutinib effectively controled leukemia development, but also resulted in significantly lower numbers of CD8+ effector T-cells, with lower expression of activation markers, as well as impaired proliferation and effector function. [Haematologica] |
|
|
|
| Researchers demonstrated that LaminA/C defined a distinct repressive nuclear compartment for X chromosome inactivation (XCI) in young HSCs, and its reduction in aged HSCs correlated with an impairment in the overall control of XCI. [Stem Cell Reports] |
| |
|
|
| Investigators retrospectively analyzed adult patients with acute lymphoblastic leukemia who underwent their first allogeneic stem cell transplantation in first or second complete remission between 2012 and 2018, either from a T cell replete Haplo or matched sibling donor donor. [Journal of Hematology & Oncology] |
|
|
|
| The authors conducted retrospective multicenter analysis of patients diagnosed with acute myeloid leukemia or myelodysplastic syndromes who had hematological relapse after allogeneic hematopoietic stem cell transplantation and were treated with azacitidine for this indication. [European Journal of Haematology] |
|
|
|
|
| Three CAR-T cell products are currently approved by the FDA, with others in clinical trials. Additional agents in development include bispecific antibodies and antibody drug conjugates. [Blood Cancer Journal] |
|
|
|
| Investigators highlight two areas in the field of HSC research, which just started to unlock the possibilities provided by novel biomaterials, in vitro blood production and studying the pathophysiology of the niche in vitro. [Acta Biomaterialia] |
|
|
|
|
| Bio-Path Holdings, Inc. announced the successful completion of the safety run-in of the Stage II of the Phase II clinical study of prexigebersen, a liposomal Grb2 antisense, for the treatment of acute myeloid leukemia (AML), in combination with frontline therapies, decitabine and venetoclax, in AML patients. [Bio-Path Holdings, Inc.] |
|
|
|
| Kite announced that it has submitted a supplemental Biologics License Application to FDA for Tecartus® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). [Kite (BusinessWire, Inc.)] |
|
|
|
|
|
|
|
| American Association for Cancer Research – Boston, Massachusetts, United States |
|
|
|
| Moores Cancer Center – La Jolla, California, United States |
|
|
|
| University of Washington – Seattle, Washington, United States |
|
|
|
| Moores Cancer Center – La Jolla, California, United States |
|
|
|
|
|